健脾养胃方联合信迪利单抗对中晚期胃癌脾胃虚弱证患者的临床疗效分析

Analysis of the Clinical Efficacy of Jianpi Yangwei Formula Combined with Sintilimab in Patients with Spleen and Stomach Deficiency Syndrome in Advanced Gastric Cancer

目的 分析应用健脾养胃方联合信迪利单抗治疗中晚期胃癌脾胃虚弱证患者的临床疗效。方法 选取2022年3月至2023年2月南阳市中心医院收治的177例中晚期胃癌脾胃虚弱证患者,根据治疗方案分为对照组(常规化疗+信迪利单抗)和观察组(常规化疗+信迪利单抗+健脾养胃方),两组患者治疗6个疗程后对比患者临床疗效差异,治疗前后患者中医证候积分、血清肿瘤标志物和营养状态变化,统计患者治疗期间不良反应发生情况。结果 观察组患者的临床缓解率及总有效率均明显优于对照组,差异有统计学意义(P <0.05)。治疗前两组患者的中医证候积分、血清癌胚抗原(CEA)、癌抗原125(CA-125)、癌抗原199(CA-199)、癌抗原242(CA-242)、癌抗原724(CA-724)、体质量指数(BMI)、血清白蛋白(HSA)和血清总蛋白(TP)结果对比差异无统计意义(P> 0.05)。治疗后两组患者中医证候积分和CEA、CA-125、CA-199、CA-242及CA-724均明显降低,且观察组中医证候积分和CEA、CA-125、CA-199、CA-242及CA-724低于对照组,差异有统计学意义(P <0.05);治疗后两组患者BMI、HSA和TP检测结果均明显增加,且观察组BMI、HSA和TP高于对照组,差异有统计学意义(P <0.05)。治疗期间观察组患者不良反应发生率明显低于对照组,差异有统计学意义(P <0.05)。结论 健脾养胃方联合信迪利单抗有助于提升中晚期胃癌脾胃虚弱证患者的临床治疗效果,并有效改善患者的营养状态,降低治疗期间不良反应发生率,应用效果理想。

Objective To analyze the clinical efficacy of Jianpi Yangwei Formula combined with Sintilimab in the treatment of patients with spleen and stomach deficiency syndrome in advanced gastric cancer.Methods A total of 177 patients with spleen and stomach deficiency syndrome in advanced gastric cancer admitted to Nanyang Central Hospital from March 2022 to February 2023 were selected.According to the treatment plan,they were divided into a control group(routine chemotherapy+Sintilimab)and an observation group(routine chemotherapy+Sintilimab+Jianpi Yangwei Formula).The clinical efficacy differences between the two groups were compared after six treatment cycles.Changes in TCM syndrome scores,serum tumor markers,and nutritional status before and after treatment were analyzed,and the incidence of adverse reactions during treatment was recorded.Results The clinical remission rate and total effective rate of the observation group were significantly better than those of the control group,with statistically significant differences(P<0.05).Before treatment,there were no statistically significant differences in TCM syndrome scores,serum carcinoembryonic antigen(CEA),cancer antigen 125(CA-125),cancer antigen 199(CA-199),cancer antigen 242(CA-242),cancer antigen 724(CA-724),body mass index(BMI),Human Serum Albumin(HSA),and total protein(TP)between the two groups(P>0.05).After treatment,TCM syndrome scores,CEA,CA-125,CA-199,CA-242,and CA-724 in both groups were significantly reduced,and the observation group’s scores were lower than those of the control group,with statistically significant differences(P<0.05).After treatment,BMI,HSA,and TP levels in both groups significantly increased,and the observation group’s levels were higher than those of the control group,with statistically significant differences(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group,with statistically significant differences(P<0.05).Conclusion Jianpi Yangwei Formula combined with Sintilimab helps improve the clinical treatment effect of patients with spleen and stomach deficiency syndrome in advanced gastric cancer,effectively improves the nutritional status of patients,reduces the incidence of adverse reactions during treatment,and has an ideal application effect.